Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Hemostat devices: Absorbable hemostat device manufacturers Johnson & Johnson/Ethicon and Danish firm Ferrosan have until June 7 to submit updated comments to FDA in opposition to a proposed down-classification of the products, which consist of wound dressing and a chemical or biological agent used to control bleeding during surgical procedures. The agency reopened the comment period after it expired in January in response to requests from the two firms for more time. The companies, which market Surgicel (Ethicon), Instat (Ethicon) and Surgifoam (Ferrosan), have already gone on the record against the reclassification, which would allow new products to enter the market based on 510(k) clearance rather than the more involved PMAs that were required for their products. FDA proposed the reclassification in October 2006 after two advisory panel meetings in 2002 and 2003. Ethicon and Ferrosan argue that FDA has not been transparent enough in its proposed rulemaking and that the suggested policy's product definition is too broad, among other issues...
Advertisement

Related Content

CDRH Chief Pushes Office To Speed Up Device Reclassifications
CDRH Chief Pushes Office To Speed Up Device Reclassifications
FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
Advertisement
UsernamePublicRestriction

Register

MT024830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel